The inhibitory effect of luteolin on cyclooxygenase (COX)-2 expression was investigated in 12-O-tetradecanoyl phorbol-13-acetate (TPA), a prototype tumor promoter, activated human lung epithelial A549 cells. Luteolin mitigated TPA-stimulated COX-2 expression in a dose-dependent manner without any cytotoxicity. Since nuclear factor (NF)-κB plays a critical role in inflammatory casdades, activated status of NF-κB was estimated through the phosphorylation of p65, one subunit of NF-κB by western blot analysis. Phosphorylation of p65 was dose-dependently inhibited by luteolin treatment. Mitogen-activated protein kinases (MAPKs) are also important signaling molecules for COX-2 regulation. Luteolin treatment inhibited TPA-induced extracellular-signal regulated protein kinase (ERK) phosphorylation that is crucially related to inflammatory cascades regulation. These results suggest that luteolin attenuates TPA-induced COX-2 expression by blocking NF-κB activation through suppressed ERK phosphorylation in A549 cells.
Introduction
Inflammation is a complex host response against various injuries. This reaction is usually delivered by immune cells, such as monocytes and macrophages, which regulate inflammatory mediators, including nitric oxide (NO), prostaglandin E2 (PGE2), and tumor necrosis factor (TNF)-α [1] . Excessive production of NO by inducible NO synthase (iNOS), the enzyme that synthesizes NO from l-arginine, is closely associated with inflammatory diseases, as well as the development of atherosclerosis and cancer [2] . Cyclooxygenase (COX) is a rate-limiting enzyme which generates prostaglandins (PGs) from arachidonic acid. Expression of this enzyme is elevated in response to tumor promoter, ultraviolet (UV) and toxic insults [3] . In response to stimuli, overproduced PGE 2 by inappropriately upregulated COX-2 usually found in various premalignant and malignant tissues [4] . COX-2 overexpression inhibited apoptosis and accelerated malignant cell invasion, which was reversed by non-steroidal ant-inflammatory agents (NSAIDs) [5] . Therefore, arachidonic acid pathway has been regarded as one of the hallmarkers for chronic inflammation. In order to eliminate inflammation, development of COX-2 inhibitors may be considered as one of promising strategies for anti-inflammatory agent [6] . The inflammatory process is also mediated through proinflammatory cytokines and chemokines, including interleukin (IL)-1, TNF-α, and IL-8, which are produced by activated macrophages.
TNF-α reportedly has played a critical role in the inflammatory cascades [7] . The expression of iNOS, COX-2, and TNF-α is regulated by nuclear factor (NF)-κB, which exists ubiquitously in the cytoplasm. This inflammatory transcription factor consists of p50 and p65 subunits bound to an inhibitory protein, IκBα. In response to inflammatory stimuli induced by the bacterial endotoxin lipopolysaccharide (LPS), IκBα is phosphorylated and released from NF-κB. The activated NF-κB subunits, p50 and p65, then migrate into the nucleus and upregulate inflammation-related genes [8] .
A549 cell line exhibits a characteristic as alveolar type II pulmonary carcinoma cells. Alveolar epithelial cells play a critical role in inflammatory cascades and its proinflammatory mediators such as IL-1β and PGE2 production [9, 10] . Phorbol esters such as 12-O-tetradecanoyl phorbol-13-acetate (TPA) can role as tumor promoters and have been reported to modulate a variety of cellular responses including gene regulation, cellular growth and differentiation, apoptosis, and immune response. TPA, proinflammatory cytokines and LPS, have been studied that they promote PGE2 production and its corresponding enzyme, COX-2 expression [11] .
COX-2 expression is regulated by a transcription factor, NF-κB. This transcription factor is activated in response to inflammatory stimuli and translocate into the nucleus; therefore, inflammation-related genes such as COX-2 and iNOS were upregulated [12, 13] . Hence, dietary phytochemicals modulating COX-2 expression by suppressing transcription factor in human cancer cells may be promising as chemopreventive agents.
Luteolin (3',4',5,7-tetrahydroxyflavone), an abundant flavonoid in celery, green pepper, parsley, and perilla leaves, plays a role as an antioxidant, anti-inflammatory agent, and free radical scavenger [14] . Luteolin inhibits LPS-induced inflammatory responses through the modulation of NF-κB and activator protein (AP)-1 modulation in RAW 264.7 and HepG2 cells [15] . The present study investigated whether luteolin modulates TPA-induced COX expression and explored its underlying molecular mechanisms in human lung adenocarcinoma A549 cells.
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Materials and Methods

Reagents
Dulbecco's modified Eagle Medium (DMEM), fetal bovine serum (FBS), and glutamine were obtained from Gibco-BRL (Gaithersburg, MD, USA). Luteolin (purity ≥98.0%),
12-O-tetradecanoyl phorbol-13-acetate (TPA) and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Antibodies against COX-2, phospho-p65, phospho-extracellular signal-regulated kinase (ERK), phospho-c-Jun NH 2 -terminal kinase (JNK), phospho-p38 and actin were purchased from Cell Signaling Technology (Danvers, MA, USA).
Cell culture and treatment
The A549 cell line was obtained from the American Type Culture Collection (Rockville, MD, USA) and cultured in DMEM supplemented with 10% FBS and 2 mM L-glutamine. Cells were incubated with the indicated concentrations of luteolin for and 10 nM of TPA for 4 hr at 37°C
in a humidified atmosphere containing 5% CO 2 .
Cytotoxicity assay
Cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) -2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay purchased from Promega (Madison, WI, USA). Cells were incubated with MTS for 1hr and quantified by measurement at OD 490 .
Western blot analysis
Cell lysates were prepared using M-PER (Pierce Biotechnology, Waltham, MA, USA), according to the manufacturer's instruction. Protein samples (50 μg) from each lysate were separated on a 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel and electrotransferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories, Hercules, CA, USA).
Membranes were blocked for 2 hr at room temperature with 5% nonfat dry milk in TBST solution. The reactions were then incubated at 4°C overnight with a 1:1,000 dilution of antibodies in blocking buffer. After the membranes were washed, they were further incubated
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Copyright ⓒ 2017 HSST 470 with a 1:1,000 dilution of horseradish peroxidase-conjugated secondary antibody for 2 hr at room temperature. The blots were developed using the Enhanced Chemiluminescence Reagent (Santa Cruz Biotechnology, SantaCruz, CA, USA), and data were quantified using the Gel Doc EQ System(Bio-Rad Laboratories).
Statistical analysis
All data are expressed as mean ± SD. Statistical analyses were performed using SPSS version 10.0 (SPSS Inc., Chicago, IL, USA). A one-way analysis of variance followed by Duncan's multiple range test was used to examine differences among the groups. P-values <0.05 were considered significant.
Results and Discussion
Many researchers have studied the anti-inflammatory activity of luteolin in various cell lines including microglia, PC12 cells, keratinocytes and HepG2 cells [16, 17] . This study was tried to investigate the inhibitory effect of luteolin on TPA-induced COX-2 expression and its underlying molecular mechanisms in A549 cells. TPA treatment activates complex signaling pathways leading to diverse cellular responses such as proliferation, differentiation, migration, transformation and invasion. In human mammary epithelial MCF10A cells, TPA-stimulation induced COX-2 overexpression in a concentration-dependent manner [5] . The present study showed that TPA treatment induced COX-2 expression when A549 cells were exposed at 10 nM for 4 hr (Fig. 1A & B) .
A)
TPA ( 
COX-2 inhibitory effect of luteolin in TPA-induced A549 cells
COX-2 expression level was measured to evaluate chemopreventive activity of luteolin in TPA-stimulated A549 cells. As shown in Fig. 2A , luteolin dose-dependently inhibited COX-2 protein expression in TPA-stimulated A549 cells without any cytotoxicity (Fig. 2B) .
A)
TPA (10 nM COX is the key enzyme that catalyzes the rate-limiting step in PG synthesis, which is existed as two isoforms, COX-1 and COX-2. COX-1 usually works as a housekeeping enzyme which is
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constitutively expressed in almost all mammalian tissues. But, COX-2 is unable to detect under normal physiological conditions. Like other early-response gene products, COX-2 can be induced by proinflammatory mediators and mitogenic stimuli including cytokines, endotoxins, growth factors, oncogenes, and phorbol ester. Several studies indicate that inappropriate upregulation of COX-2 is implicated in the promotion and progression stages [18] . Thus, COX-2 inhibitors have been recognized as a molecular target of chemopreventive and anti-inflammatory agents [15] [19] . In this study, TPA treatment dramatically induced COX-2 overexpression, which was ameliorated by luteolin treatment in a dose-dependent manner.
Downregulation of NF-κB and ERK in TPA-induced A549 cells
To assess underlying molecular mechanisms of luteolin, NFκB and its upstream signaling molecules, mitogen activated protein kinases (MAPKs), were measured by Western blot analysis.
Since NF-κB plays an essential role in regulation of inflammatory mediators, phosphorylation levels of IκBα and p65 were analyzed. As shown in Fig. 3A , luteolin treatment inhibited p65 phosphorylation in TPA-stimulated A549 cells. A critical transcription factor in inflammation pathways, NF-κB, was also regulated by luteolin treatment. Macrophages activated by inflammatory stimuli accelerate IκBα phosphorylation, which leads to its subsequent degradation by the 26S proteasome [20] . The liberated NF-κB then translocates into the nucleus and binds to NF-κB binding sites in the promoter regions of inflammatory mediators [21] . Induction of NF-κB up-regulates COX-2 and pro-inflammatory cytokines, including TNF-α and IL-1β. NF-κB is considered to be a critical target for treatments that aim to inhibit inflammatory responses [22] .
A)
TPA ( A549 cells were incubated with and without the indicated luteolin and TPA for 4 hr. Actin was used as an internal control.
The MAPK pathways play a critical role in the regulation of inflammation [23] . To examine whether luteolin pretreatment affects MAPK inactivation, phosphorylated levels of ERK, JNK, and p38 were measured by Western blot analysis in TPA-stimulated A549 cells. As shown in Fig. 3B , luteolin treatment inhibited ERK phosphorylation, but had no visible effect on JNK or p38 phosphorylation. These results suggest that inactivating ERK by luteolin treatment may contribute to reduce TPA-induced NF-κB activation and consequently reduce COX-2 expression in A549 cells. It has been reported that NF-κB activation inflammatory stimuli are followed by a cascade of events that lead to MAPK activation [20] . Three distinct groups of well characterized major MAPK subfamily members include ERK, JNK, and p38 MAPKs, which are serine/threonine protein kinases [24] . All of these MAPKs are activated through dual phosphorylation at tyrosine and threonine by an upstream MAPK kinase in response to a wide array of extracellular stimuli. The activated form of the MAPKs then phosphorylates and activates other kinases or transcription factors, thereby altering target gene expression. Our findings showed that the inhibitory effect of luteolin on TPA-induced COX-2 expression was mediated by NF-κB inactivation through the ERK pathway.
In conclusion, luteolin modulated COX-2 expression via NF-κB inactivation regulated by the ERK pathway in A549 cells. These results suggest that luteolin may be utilized as a potential chemopreventive agent by modulating COX-2 expression.
